Trial Profile
Single-Arm, Open Label, Interventional Phase II Clinical Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Feb 2024
Price :
$35
*
At a glance
- Drugs Busulfan (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Granulocyte colony-stimulating factors (Primary) ; Melphalan (Primary) ; Mycophenolate mofetil (Primary) ; Mycophenolate mofetil (Primary) ; Spanlecortemlocel (Primary) ; Tacrolimus (Primary)
- Indications Haematological malignancies
- Focus Therapeutic Use
- 06 Jul 2023 Planned End Date changed from 28 Apr 2023 to 28 Jun 2024.
- 02 Nov 2022 Planned End Date changed from 1 Aug 2023 to 28 Apr 2023.
- 02 Nov 2022 Planned primary completion date changed from 1 Jul 2023 to 31 Mar 2023.